Last reviewed · How we verify
lapatinib and Vinorelbine
At a glance
| Generic name | lapatinib and Vinorelbine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs (PHASE3)
- SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
- A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer (PHASE2)
- Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer (PHASE1, PHASE2)
- Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer (PHASE1, PHASE2)
- Lapatinib in Combination With Vinorelbine (PHASE2)
- Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lapatinib and Vinorelbine CI brief — competitive landscape report
- lapatinib and Vinorelbine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI